Posted by Michael Wonder on 16 May 2019
Instalment payments could be used across gene therapy space, Spark CEO says
16 May 2019 - In a fireside chat at the recently concluded Veeva Summit in Philadelphia, Jeff Marrazzo said payment over time is important for gene therapies, but the pace of policy making by government is too slow.
Payments over time are an attractive model for paying for expensive gene therapies, but things need to move faster on the policy end, the head of the first company to win Food and Drug Administration approval for a gene therapy said Wednesday.
Speaking in a fireside chat at Veeva’s North America Commercial & Medical Summit in Philadelphia, Spark Therapeutics CEO Jeff Marrazzo expressed disappointment that policies to enable such installment payments for gene therapies were taking a long time to be put in place at the Centers for Medicare and Medicaid Services.
